Matches in SemOpenAlex for { <https://semopenalex.org/work/W2146289920> ?p ?o ?g. }
- W2146289920 endingPage "199" @default.
- W2146289920 startingPage "196" @default.
- W2146289920 abstract "Thalidomide was recently reintroduced to treat several immune-mediated pathologies. Peripheral neuropathy is a significant side effect limiting its clinical use. Our aims include: (1) describing and identifying the incidence of clinical or electrophysiologic peripheral neuropathy in children, (2) determining whether peripheral neuropathy correlates with cumulative dose of thalidomide and with age, and (3) defining its reversibility rate. We studied 13 children manifesting immune-mediated pathologies treated with thalidomide at doses ranging from 25-100 mg/day. Clinical and neurophysiologic evaluation was performed before and after starting treatment. Seven children (53.8%) showed neurophysiologic signs of sensory peripheral axonal polyneuropathy. Five presented associated clinical symptoms, while the other two only presented subclinical, neurophysiologic signs of peripheral neuropathy. We found a significant correlation between the incidence of peripheral neuropathy and thalidomide cumulative dose (P = 0.02). We observed a lower incidence of peripheral neuropathy at a cumulative dose <20 gm, and a correlation with age (P < 0.01). The clinical and electrophysiologic recovery rate was 40%, and clinical improvement alone was observed in another 40%. Thalidomide induces dose-dependent and age-dependent peripheral neuropathy at a significant frequency in childhood (53.8%). In our experience a cumulative dosage at >20 gm and long-term administration for >10 months seem to increase the risk of peripheral neuropathy. We propose clinical and neurophysiologic follow-up every 3 months to identify and monitor possible side effects. Thalidomide was recently reintroduced to treat several immune-mediated pathologies. Peripheral neuropathy is a significant side effect limiting its clinical use. Our aims include: (1) describing and identifying the incidence of clinical or electrophysiologic peripheral neuropathy in children, (2) determining whether peripheral neuropathy correlates with cumulative dose of thalidomide and with age, and (3) defining its reversibility rate. We studied 13 children manifesting immune-mediated pathologies treated with thalidomide at doses ranging from 25-100 mg/day. Clinical and neurophysiologic evaluation was performed before and after starting treatment. Seven children (53.8%) showed neurophysiologic signs of sensory peripheral axonal polyneuropathy. Five presented associated clinical symptoms, while the other two only presented subclinical, neurophysiologic signs of peripheral neuropathy. We found a significant correlation between the incidence of peripheral neuropathy and thalidomide cumulative dose (P = 0.02). We observed a lower incidence of peripheral neuropathy at a cumulative dose <20 gm, and a correlation with age (P < 0.01). The clinical and electrophysiologic recovery rate was 40%, and clinical improvement alone was observed in another 40%. Thalidomide induces dose-dependent and age-dependent peripheral neuropathy at a significant frequency in childhood (53.8%). In our experience a cumulative dosage at >20 gm and long-term administration for >10 months seem to increase the risk of peripheral neuropathy. We propose clinical and neurophysiologic follow-up every 3 months to identify and monitor possible side effects." @default.
- W2146289920 created "2016-06-24" @default.
- W2146289920 creator A5016968796 @default.
- W2146289920 creator A5022514890 @default.
- W2146289920 creator A5022610031 @default.
- W2146289920 creator A5029201337 @default.
- W2146289920 creator A5031502375 @default.
- W2146289920 creator A5045115320 @default.
- W2146289920 creator A5053040386 @default.
- W2146289920 creator A5056424358 @default.
- W2146289920 creator A5082235608 @default.
- W2146289920 creator A5084554315 @default.
- W2146289920 creator A5091749616 @default.
- W2146289920 creator A5091882501 @default.
- W2146289920 date "2008-03-01" @default.
- W2146289920 modified "2023-09-27" @default.
- W2146289920 title "Childhood Thalidomide Neuropathy: A Clinical and Neurophysiologic Study" @default.
- W2146289920 cites W1982377576 @default.
- W2146289920 cites W1988898930 @default.
- W2146289920 cites W1993653904 @default.
- W2146289920 cites W1994145103 @default.
- W2146289920 cites W2017698354 @default.
- W2146289920 cites W2043046274 @default.
- W2146289920 cites W2046285825 @default.
- W2146289920 cites W2054666453 @default.
- W2146289920 cites W2065927548 @default.
- W2146289920 cites W2080754222 @default.
- W2146289920 cites W2113827087 @default.
- W2146289920 cites W2146126581 @default.
- W2146289920 cites W2155039923 @default.
- W2146289920 cites W2166873037 @default.
- W2146289920 cites W2313493986 @default.
- W2146289920 cites W2323334765 @default.
- W2146289920 doi "https://doi.org/10.1016/j.pediatrneurol.2007.11.004" @default.
- W2146289920 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18279755" @default.
- W2146289920 hasPublicationYear "2008" @default.
- W2146289920 type Work @default.
- W2146289920 sameAs 2146289920 @default.
- W2146289920 citedByCount "23" @default.
- W2146289920 countsByYear W21462899202012 @default.
- W2146289920 countsByYear W21462899202014 @default.
- W2146289920 countsByYear W21462899202015 @default.
- W2146289920 countsByYear W21462899202016 @default.
- W2146289920 countsByYear W21462899202017 @default.
- W2146289920 countsByYear W21462899202018 @default.
- W2146289920 countsByYear W21462899202022 @default.
- W2146289920 crossrefType "journal-article" @default.
- W2146289920 hasAuthorship W2146289920A5016968796 @default.
- W2146289920 hasAuthorship W2146289920A5022514890 @default.
- W2146289920 hasAuthorship W2146289920A5022610031 @default.
- W2146289920 hasAuthorship W2146289920A5029201337 @default.
- W2146289920 hasAuthorship W2146289920A5031502375 @default.
- W2146289920 hasAuthorship W2146289920A5045115320 @default.
- W2146289920 hasAuthorship W2146289920A5053040386 @default.
- W2146289920 hasAuthorship W2146289920A5056424358 @default.
- W2146289920 hasAuthorship W2146289920A5082235608 @default.
- W2146289920 hasAuthorship W2146289920A5084554315 @default.
- W2146289920 hasAuthorship W2146289920A5091749616 @default.
- W2146289920 hasAuthorship W2146289920A5091882501 @default.
- W2146289920 hasConcept C113280763 @default.
- W2146289920 hasConcept C120665830 @default.
- W2146289920 hasConcept C121332964 @default.
- W2146289920 hasConcept C126322002 @default.
- W2146289920 hasConcept C134018914 @default.
- W2146289920 hasConcept C141071460 @default.
- W2146289920 hasConcept C151032500 @default.
- W2146289920 hasConcept C2775892965 @default.
- W2146289920 hasConcept C2776364478 @default.
- W2146289920 hasConcept C2779609412 @default.
- W2146289920 hasConcept C2779901536 @default.
- W2146289920 hasConcept C2911091166 @default.
- W2146289920 hasConcept C42219234 @default.
- W2146289920 hasConcept C46762472 @default.
- W2146289920 hasConcept C555293320 @default.
- W2146289920 hasConcept C61511704 @default.
- W2146289920 hasConcept C71924100 @default.
- W2146289920 hasConcept C88879693 @default.
- W2146289920 hasConcept C90924648 @default.
- W2146289920 hasConceptScore W2146289920C113280763 @default.
- W2146289920 hasConceptScore W2146289920C120665830 @default.
- W2146289920 hasConceptScore W2146289920C121332964 @default.
- W2146289920 hasConceptScore W2146289920C126322002 @default.
- W2146289920 hasConceptScore W2146289920C134018914 @default.
- W2146289920 hasConceptScore W2146289920C141071460 @default.
- W2146289920 hasConceptScore W2146289920C151032500 @default.
- W2146289920 hasConceptScore W2146289920C2775892965 @default.
- W2146289920 hasConceptScore W2146289920C2776364478 @default.
- W2146289920 hasConceptScore W2146289920C2779609412 @default.
- W2146289920 hasConceptScore W2146289920C2779901536 @default.
- W2146289920 hasConceptScore W2146289920C2911091166 @default.
- W2146289920 hasConceptScore W2146289920C42219234 @default.
- W2146289920 hasConceptScore W2146289920C46762472 @default.
- W2146289920 hasConceptScore W2146289920C555293320 @default.
- W2146289920 hasConceptScore W2146289920C61511704 @default.
- W2146289920 hasConceptScore W2146289920C71924100 @default.
- W2146289920 hasConceptScore W2146289920C88879693 @default.
- W2146289920 hasConceptScore W2146289920C90924648 @default.
- W2146289920 hasIssue "3" @default.